Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SACLA: Subretinal Monteplase for Submacular Hemorrhage
jRCT2071250003Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Aug 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of monteplase in submacular hemorrhage (SMH), age-related macular degeneration (AMD) and Retinal arterial macroaneurysm (RAM), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary: Change in central foveal retinal thickness at Week 1. Started Aug 2025; status: recruiting.
02
Drugs
monteplase
03
Conditions
submacular hemorrhage (SMH)age-related macular degeneration (AMD)Retinal arterial macroaneurysm (RAM)
Beyond the preview
Go deeper on jRCT2071250003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250003.